The draft guidance issued Tuesday comes as regulators and policymakers have looked for ways to aid U.S. drugmakers amid fast progress by their China-based counterparts.

Myocardial ischemia, a disorder associated with high rates of morbidity and mortality, is one of the most extensively studied topics in modern cardiovascular research. The condition is characterized ...